University of Milan

Dr. Jinzi J. Wu Presents at the 10th International Workshop on HBV Cure 2023

Retrieved on: 
Thursday, November 9, 2023
Massachusetts General Hospital, Patient, HKEX, Research, PD-L1, Hepatitis B virus, Trial of the century, Harvard Medical School, AIDS, National Institutes of Health, Lim, Johns Hopkins University, Arbutus, Prevalence, Jacob Aligo, Safety, PD-1, University of Milan, CHB, University of Hong Kong, Virus, Phase, Immunotherapy, Risk, HIV/AIDS research, International Workshop on Lung Health, Bangladesh Technical Education Board, GSK, University, Roche, HBsAg, VIR, University of Oxford, Toronto Centre, Liver disease, HBV, Hook effect, Village Vanguard Live Sessions 3, Vaccine, Pharmaceutical industry, Northwestern University, Immunocore

HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.

Key Points: 
  • HANGZHOU and SHAOXING, China, Nov. 8, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis was invited to attend and have a presentation at the 10th International Workshop on HBV Cure 2023 held at Boston, United States.
  • The interim analysis included 25 patients who completed 24-week treatment (19 patients in ASC22 cohort and 6 patients in placebo cohort).
  • Topline results indicated that in ASC22 cohort, 4 patients (4/19, 21.1%) achieved HBsAg loss at the end of 24-week treatment.
  • "It's a great honor to be invited to the 10th International Workshop on HBV Cure 2023 and share our latest progress in developing the immune checkpoint inhibitor for functional cure of CHB with the global industry.

Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy

Retrieved on: 
Friday, November 3, 2023
FDA, Health, Stem Cells, General Health, Pharmaceutical, Biotechnology, Patient, University of Milan, Society, Poster, ASH, Efficacy, Corporation, University, Abstract, Dentistry, Hematology, Adult

Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had “high-risk” TA-TMA.

Key Points: 
  • Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), 14 of whom had “high-risk” TA-TMA.
  • Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.
  • The report was authored by an external group of investigators involved in the treatment of these patients with narsoplimab provided under Omeros’ compassionate use program.
  • Details of the presentation are as follows:
    Clinical Safety and Efficacy of Narsoplimab in Pediatric and Adult Patients with Transplant-Associated Thrombotic Microangiopathy: A Real-World Experience (Abstract #3543)

Implantica's RefluxStop™ made a substantial impact at the American Foregut Society (AFS)

Retrieved on: 
Tuesday, October 10, 2023
Annual general meeting, General surgery, Esophagus, AFS, Division, European, Deutsche Medizinische Wochenschrift, University, University of Southern California, CEST, Dysphagia, Gastroenterology, CE, University of Milan, Associate, Surgeon, Certification, Clinic, Patient, Gastroesophageal reflux disease, Hiatal hernia, Dentistry, Hospital, GERD

), a medtech company at the forefront of bringing advanced technology into the body, successfully attended the American Foregut Society (AFS) 2023 Annual Meeting held in Dallas, Texas.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, successfully attended the American Foregut Society (AFS) 2023 Annual Meeting held in Dallas, Texas.
  • The meeting included a panel discussion on RefluxStop with 4 leading European KOLs and was moderated by the former president of AFS.
  • The panel reviewed and discussed the promising outcomes data from over 500 RefluxStop procedures performed in Europe.
  • "It is rewarding that outcomes achieved during the CE study can be replicated in a real-world setting.

Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease

Retrieved on: 
Monday, September 11, 2023
Epilepsy, Yale University, University, Phosphorylation, Cassava, Cassava Sciences, Research, Doctor of Philosophy, Dementia, CUNY School of Labor and Urban Studies, CNRS, Patient, Canadian International Council, SPA, FLNA, Seizure, Mouse, CUNY School of Medicine, International Journal of Molecular Sciences, University of Milan, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Environmental Molecular Sciences Laboratory, Food, Medicine, Pharmaceutical industry, Medical imaging, Neuroscience, Inserm

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam.

Key Points: 
  • AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam.
  • Simufilam is Cassava Sciences’ novel drug candidate for people with Alzheimer’s disease dementia and is currently under evaluation in a pair of global Phase 3 clinical trials.
  • Cassava Sciences believes this protein interaction underlies simufilam’s mechanism of action in Alzheimer’s disease.
  • Cassava Sciences is evaluating simufilam oral tablets for Alzheimer’s disease dementia in two global Phase 3 clinical studies.

New Scientific Study Confirms 80% Methane Emission Reduction From Dairy Manure Using SOP® Lagoon

Retrieved on: 
Tuesday, June 20, 2023
Research, Professional Services, Agriculture, Natural Resources, Environment, Other Manufacturing, Green Technology, Science, Chemicals, Plastics, Environmental, Social and Governance (ESG), Manufacturing, Other Science, Carbon, Methane, University of California, Davis, University, Climate, Tillamook County Creamery Association, Farmer, Greenhouse gas, Overalls, Carbon dioxide, Policy, GHG, Multimedia, Temperature, Nitrous oxide, Certification, Milk, Resonance, Sustainability, Animal, Soil, UC, Ammonia, UN, Manure, Carbon credit, ESG, CH4, University of Milan, NH3, Health, CO2, Renewable energy, Dairy, Coal, EU

The results show that Resonant’s solution is the only additive that so successfully mitigates lagoon dairy waste releases that are responsible for up to 57% of total dairy methane emissions.

Key Points: 
  • The results show that Resonant’s solution is the only additive that so successfully mitigates lagoon dairy waste releases that are responsible for up to 57% of total dairy methane emissions.
  • SOP® Lagoon was developed by the Italian firm Save Our Planet (“SOP”) and is marketed by Resonant.
  • The University of Milan study concludes that SOP® Lagoon can significantly reduce the methane and other emissions.
  • To put that in context, dairy cows alone are responsible for 8% of global methane pollution.

Agios to Present Clinical and Translational Data at European Hematology Association Annual Congress

Retrieved on: 
Thursday, May 11, 2023
Abstract, RBC, CDL, Pyruvate kinase deficiency, Pharmacy, University, Iron overload, European Hematology Association, Vall d'Hebron University Hospital, Hemolysis, University Medical Center, Effect, Sickle cell disease, Department of Medicine – University of Pamplona, Rated R, Teaching hospital, Harvard Medical School, AGIO, Hematologic disease, Congress, University of Milan, Pyruvate kinase, University Medical Center Utrecht, Translational research, Treatment, University of Verona, CEST, EHA, Utrecht University, Red blood cell, Clinical, Patient, Agios Pharmaceuticals, Rare, Palacký University Olomouc, Myelodysplastic syndrome, Fondazione Child, Dietary supplement, Pharmaceutical industry, Nursing, Doctor of Philosophy, Cancer

CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company and its collaborators will present a broad range of clinical and translational data at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Frankfurt, Germany, June 8-11, 2023, and continuing virtually on the Congress platform June 14-15, 2023.

Key Points: 
  • – Agios to Present New Analyses from ACTIVATE, ACTIVATE-T and Long-Term Extension Studies in Adults with PK Deficiency Reinforcing Clinical Benefit of PYRUKYND® (mitapivat) on Hemoglobin, Hemolysis, Iron Overload and Patient-Reported Outcomes –
    CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that the company and its collaborators will present a broad range of clinical and translational data at the European Hematology Association (EHA) Hybrid Congress, hosted virtually and in person in Frankfurt, Germany, June 8-11, 2023, and continuing virtually on the Congress platform June 14-15, 2023.
  • The accepted abstracts are listed below and are available online on the EHA meeting library website.
  • All posters will be presented during the poster session on Friday, June 9 at 16:30-17:45 CEST.
  • All presentations can be accessed on demand by registered meeting attendees on the EHA Virtual Congress platform until Aug. 15, 2023.

Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio

Retrieved on: 
Friday, May 5, 2023
Biotechnology, Health, Oncology, Clinical Trials, Gilead Sciences, KOL, Medical Affairs Bureau, AACR, University, Neoplasm, BeiGene, EVP, Cancer, Compensated emancipation, EST, Research, Medicine, Immunotherapy, Language, AstraZeneca, Institutional review board, Euronext Paris, Novartis, Acquisition, MD, Patient, Melanoma, CEST, Hematology, Cell, Professional Football Compensation Committee, Pleasure, Potyvirus, Century, Growth, University of Milan, Kite Pharma, Phase, Therapy, Management, Pharmaceutical industry, Fine chemical, Vaccine, Axicabtagene ciloleucel, EU, TG4050, Transgene

The Board has appointed Dr Alessandro Riva, MD, as the Company’s new Chairman and CEO to accelerate the development of Transgene’s innovative immunotherapy portfolio.

Key Points: 
  • The Board has appointed Dr Alessandro Riva, MD, as the Company’s new Chairman and CEO to accelerate the development of Transgene’s innovative immunotherapy portfolio.
  • Dr Alessandro Riva, new CEO and Chairman of the Board, commented: “I am excited to become the CEO of Transgene at this crucial time in the company’s development.
  • I look forward to working with the team to unlock the full value of our innovative pipeline.
  • Based on these very encouraging data, Transgene confirms its decision to move forward with the development of TG4050.

Implantica Announces Another Major European Center of Excellence in Italy starting with the RefluxStop™ procedure

Retrieved on: 
Thursday, April 6, 2023
Vomiting, Surgeon, Stomach, University, Newsweek, Dysphagia, Abdominal distension, General surgery, Associate, Gastroesophageal reflux disease, GERD, Hospital, Patient, EFS, Statista, AIRES, Esophagitis, Medication, University of Milan, Disease, Pharmaceutical industry, Dentistry

The two RefluxStop™ procedures were successfully performed by Professor Davide Bona, Director of the General Surgery Operative Unit at I.R.C.C.S.

Key Points: 
  • The two RefluxStop™ procedures were successfully performed by Professor Davide Bona, Director of the General Surgery Operative Unit at I.R.C.C.S.
  • The use of medication to manage GERD is intended to be a short-term solution for those well managed by it.
  • "This innovative minimally invasive surgical procedure allows for the treatment of gastroesophageal reflux by restoring the normal physiology of the esophagogastric junction.
  • "Implantica is incredibly proud to partner with Professor Bona and Professor Bonavina representing one of Europe's foremost anti-reflux centers based in Italy.

Sonata Therapeutics Strengthens Leadership Team with Appointment of Francesco Marincola, M.D., as Chief Scientific Officer

Retrieved on: 
Tuesday, March 21, 2023
Society, Drug development, University, Therapy, Senior, Stanford University, CSO, Cancer, Infection, SITC, Immunotherapy, Sidra Medical and Research Center, Research, Cell, Practice, Bangladesh Technical Education Board, Immunogenetics, National Cancer Institute, Society for Immunotherapy of Cancer, AbbVie, Bone marrow, Neoplasm, University of Milan, Kite Pharma, NCI, NIH, Pharmaceutical industry, Sonata

WATERTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Sonata Therapeutics Inc., a biotechnology company creating therapeutics that transform diseased cells into coordinators of cure, today announced the appointment of Francesco Marincola, M.D., as Chief Scientific Officer.

Key Points: 
  • WATERTOWN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Sonata Therapeutics Inc., a biotechnology company creating therapeutics that transform diseased cells into coordinators of cure, today announced the appointment of Francesco Marincola, M.D., as Chief Scientific Officer.
  • “We are excited to welcome Franco to Sonata as its new CSO,” said Volker Herrmann, M.D., President and Chief Executive Officer of Sonata.
  • “Throughout his successful career across academia and industry over the last few decades, Franco has stood at the forefront of discovery and drug development.
  • Prior to Kite, he held numerous industry roles, including President and Chief Scientific Officer at Refuge Biotechnologies, Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.

Copan Diagnostics Announces Leadership Change

Retrieved on: 
Thursday, February 2, 2023
Artificial intelligence, Health care, Pharmaceutics, Commercial, Pleasure, University of Milan, Marketing, Microbiology, Patient, University, Medical Affairs Bureau, Merck, Sadness, Partnership, Collection, Management, Chemistry

CARLSBAD, Calif., Feb. 2, 2023 /PRNewswire/ -- COPAN Group announces the departure of Norman Sharples, Chief Executive Officer of Copan Diagnostics, from the Company he co-founded with Daniele Triva in 1994 and the appointment of Fabrizio Mazzocchi as new CEO and member of Copan Diagnostics' board of directors effective from January 9th, 2023.

Key Points: 
  • CARLSBAD, Calif., Feb. 2, 2023 /PRNewswire/ -- COPAN Group announces the departure of Norman Sharples, Chief Executive Officer of Copan Diagnostics, from the Company he co-founded with Daniele Triva in 1994 and the appointment of Fabrizio Mazzocchi as new CEO and member of Copan Diagnostics' board of directors effective from January 9th, 2023.
  • It has been a privilege to serve as COPAN Diagnostics CEO and member of the board for almost three decades.
  • "It is with a mix of sadness and gratitude that we communicate this change in leadership.
  • "It's an honor for me to join COPAN Diagnostics and be part of COPAN.